查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年的药物传输市场预测：按类型、容量、配销通路、应用和区域进行的全球分析
市场调查报告书
商品编码
1383356

到 2030 年的药物传输市场预测：按类型、容量、配销通路、应用和区域进行的全球分析

Drug Delivery Market Forecasts to 2030 - Global Analysis By Type, Capacity, Distribution Channel, Application and By Geography.
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球给药市场规模将达到 202 亿美元，预计到 2030 年将达到 355 亿美元，预测期内复合年增长率为 8.4%。

药物传递是指以受管制和有针对性的方式将药物或治疗剂等药用物质给药到人体的过程。提高药物治疗效果、减少副作用、提高患者依从性至关重要。它们在提高医疗保健和患者照护的整体品质方面发挥着重要作用。

根据美国心臟协会统计，2019年全球有1亿015亿中风患者。缺血性中风7720万例，脑出血2070万例，蜘蛛膜下腔出血840万例。

精准医疗的兴起

精准医学根据个体的遗传、基因组和生理特征量身订做医疗治疗，包括药物治疗。这种方法需要精确的药物输送系统，能够高精度地针对特定的分子途径和细胞。因此，药物传递技术不断发展以满足个人化医疗的需求，允许在体内的特定时间和位置给药精确的给药。这确保了正确的治疗到达正确的患者，最大限度地提高治疗效果，同时最大限度地减少副作用。

开发成本高

新的药物输送技术的研究和开发，从改进的配方到先进的输送系统，在经济上是负担重的。这些成本包括临床前研究、临床试验、监管核准、製造流程等。最先进的药物传输系统所需的复杂性和创新进一步推高了成本。此外，高昂的开发成本会阻碍中小企业进入市场并减慢创新步伐。这将需要大量的财务投资，挑战公司将具有成本效益的解决方案推向市场，并最终影响先进药物输送方法的可及性和可负担性。这将会是。

远端医疗和远端监控的成长

远端医疗和远端患者监护的成长为药物输送市场带来了巨大的机会。远端医疗的普及使患者能够在自己舒适的家中接受医疗服务，减少了亲自到诊所就诊的需要。这种向远端医疗的转变正在创造对创新药物输送系统的需求，这些系统使患者能够在远端医疗监督下有效、安全地自我给药给药。无论是管理慢性疾病或提供关键治疗方法，这些远距药物传输解决方案都可以提高患者的依从性、治疗结果和整体医疗保健效率。随着远端医疗的持续发展，药物传输市场将需要开发和提供以患者为中心的新技术，以适应不断发展的医疗传递环境，并最终提高药物治疗的可及性和有效性。

网路安全风险

网路安全风险对药物输送市场构成越来越大的威胁。随着药物输送系统变得更加互联并且更加依赖数位技术，它们变得更容易受到网路攻击。恶意行为者可能会损害这些系统的安全性和功能，从而危及病人安全和药物给药的完整性。此类攻击可能导致诈欺的给药、诈欺的患者资料存取以及系统故障。确保这些设备的网路安全势在必行，因为违规可能会造成严重后果，并损害患者的信任和行业声誉。

COVID-19 的影响

由于住院人数减少、供应链中断和製造业暂时停顿等因素，COVID-19 的爆发扰乱了世界各地医疗保健产业的工作流程。这种疾病迫使许多行业暂时关闭，包括医疗保健的几个子领域。疫情期间，由于药品供应中断，全球给药市场受到中度影响。然而，随着COVID-19疫苗的推出和大规模疫苗接种运动，製造商显着加快了注射给药系统的生产，以满足全球医疗需求。由于医院就诊人数的增加和先进给药系统的推出，预计疫情后市场将大幅成长。

植入式药物传输领域预计将成为预测期内最大的领域

植入式药物传输领域估计占最大份额。植入式药物传输是药物传输市场的一个专门领域，涉及使用旨在将药物直接输送到体内以进行受控和缓释性的医疗设备。这些装置通常植入皮下或某些身体组织内，可以长时间给药药物，从而减少频繁给药的需要。植入式药物传输系统可用于多种医疗应用，包括糖尿病等慢性疾病的治疗和疼痛管理，为患者提供便利性并改善治疗结果，同时最大限度地减少潜在的副作用。该领域是提高药物疗效和患者依从性的创新方法。

预计心血管疾病在预测期内的复合年增长率最高

预计心血管疾病领域在预测期内将出现良好的成长。心血管疾病（CVD）是药物输送市场的一个重要且多方面的部分。该领域致力于开发创新的药物传输系统和治疗方法，以预防、管理和治疗高血压、冠状动脉疾病、心臟衰竭、中风等。 CVD 药物传输技术包括多种解决方案，包括控制释放製剂、防止动脉阻塞的药物涂层支架以及抗凝血剂和抗血小板药物的新型输送方法。这些进步提高了药物疗效，提高了患者的依从性，并降低了不利事件的风险。此外，由于心血管疾病是全球死亡的主要原因，心血管药物输送市场有望透过提供有助于更好的结果和整体心血管健康的解决方案来缓解这一公共卫生危机。

比最大的地区

在估计期间，亚太地区占据最大的市场占有率。该地区市场扩张的主要原因是癌症发病率的上升以及公众对癌症治疗知识的不断增加。亚太地区人口众多，近年来，由于生活方式的改变、环境因素和人口高龄化，癌症发生率呈上升趋势。因此，接受治疗的患者数量不断增加，药品分发的需求也不断增加。此外，可支配所得不断增加且市场参与企业俱有良好潜力的亚太地区预计将在预测期内呈现最高成长率。此外，印度製造商正在提高产能，以满足对注射器不断增长的需求，从而推动全部区域的市场成长。

复合年增长率最高的地区：

预计北美在预测期内将实现盈利成长。这是由于糖尿病、癌症和呼吸道过敏等慢性疾病的增加、患者对新给药技术的医嘱遵从性提高以及该地区名人的高度集中。随着许多主要企业进入这一领域，市场正在不断扩大，包括诺华公司、辉瑞公司、霍夫曼拉罗氏有限公司和默克公司。此外，随着生物製药产业开发出大量可治疗多种非传染性疾病的新药，北美对药物传递解决方案的需求正在迅速增加。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球药物输送市场：依类型

  • 介绍
  • 注射给药
  • 经皮经皮
  • 口服给药
  • 局部给药
  • 粘膜给药
  • 植入式药物输送
  • 眼科药物输送
  • 其他类型

第6章全球药物传输市场：依设备类型

  • 介绍
  • 高级型
  • 传统的

第7章全球药物输送市场：依配销通路

  • 介绍
  • 零售药房
  • 医院药房
  • 线上药房
  • 其他配销通路

第8章全球药物传输市场：依应用分类

  • 介绍
  • 瘤
  • 心血管疾病
  • 糖尿病
  • 中枢神经系统疾病
  • 呼吸系统疾病
  • 其他用途

第9章全球药物输送市场：依最终用户分类

  • 介绍
  • 居家医疗
  • 医院和诊所
  • 门诊手术中心
  • 其他最终用户

第10章全球药物输送市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Abbott
  • Bayer
  • AstraZeneca
  • Sanofi
  • GlaxoSmithKline
  • La Roche
  • Johnson & Johnson
  • Novartis AG
  • Merck
  • Pfizer
  • Antares Pharma
  • GSK
  • Accord Healthcare
  • Becton Dickinson and Co
  • Boston Scientific Corp
  • Baxter International Inc
  • Kindeva Drug Delivery LP
  • Gerresheimer AG
  • Sever Pharma Solutions
  • Boehringer Ingelheim International
Product Code: SMRC24206

According to Stratistics MRC, the Global Drug Delivery Market is accounted for $20.2 billion in 2023 and is expected to reach $35.5 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Drug delivery refers to the process of administering pharmaceutical substances, such as drugs or therapeutic agents, to the human body in a controlled and targeted manner. It is essential for improving the therapeutic impact of pharmaceuticals, reducing side effects, and enhancing patient compliance. It plays a critical role in advancing medical treatments and the overall quality of patient care.

According to the American Heart Association, 101.5 million stroke cases worldwide in 2019. Ischemic stroke cases were 77.2 million, intracerebral hemorrhage cases were 20.7 million, and subarachnoid hemorrhage cases were 8.4 million.

Market Dynamics:

Driver:

Rise in precision medicine

Precision medicine tailors medical treatments, including drug therapies, to an individual's unique genetic, genomic, and physiological characteristics. This approach demands precise drug delivery systems that can target specific molecular pathways or cells with high accuracy. As a result, drug delivery technologies have evolved to accommodate the requirements of personalised medicine, enabling the administration of precise dosages at specific times and locations in the body. This ensures that the right treatment reaches the right patient, maximising therapeutic effectiveness while minimising side effects.

Restraint:

High development costs

Researching and developing new drug delivery technologies, from formulation enhancements to advanced delivery systems, can be a financial burden. These costs encompass pre-clinical testing, clinical trials, regulatory approvals, and manufacturing processes. The complexity and innovation required for cutting-edge drug delivery systems further drive up expenses. Moreover, these high development costs can deter smaller companies from entering the market and may slow down the pace of innovation. It necessitates substantial financial investments and makes it challenging for companies to bring cost-effective solutions to market, ultimately affecting the accessibility and affordability of advanced drug delivery methods.

Opportunity:

Growth of telemedicine and remote monitoring

The growth of telemedicine and remote patient monitoring presents a substantial opportunity for the drug delivery market. Telehealth's expanding popularity allows patients to access healthcare services from the comfort of their homes, reducing the need for in-person clinic visits. This shift towards remote care creates a demand for innovative drug delivery systems that enable patients to self-administer medications effectively and safely under remote medical supervision. Whether it's managing chronic conditions or delivering critical therapies, these remote drug delivery solutions can improve patient compliance, treatment outcomes, and overall healthcare efficiency. As telemedicine continues to gain momentum, the drug delivery market has the potential to develop and offer new, patient-centric technologies that align with the evolving landscape of healthcare delivery, ultimately enhancing the accessibility and effectiveness of drug treatments.

Threat:

Cybersecurity risks

Cybersecurity risks represent a growing threat to the drug delivery market. As drug delivery systems become increasingly interconnected and reliant on digital technologies, they become susceptible to cyber attacks. Malicious actors could potentially compromise the security and functionality of these systems, endangering patient safety and the integrity of drug administration. Such attacks may lead to incorrect dosing, unauthorised access to patient data, or system failures. Ensuring the cybersecurity of these devices is imperative, as breaches can have severe consequences, eroding patient trust and industry reputation.

COVID-19 Impact

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world due to factors such as reduced hospital admissions, disruptions in the supply chain, temporary halts in manufacturing, and others across the globe. The disease has forced a number of industries to temporarily shut their doors, including several sub-domains of health care. The global pharmaceutical drug delivery market was moderately impacted during the pandemic due to disruptions in the supply of pharmaceutical products. However, with the launch of COVID-19 vaccines and mass vaccination drives, there was a significant acceleration in manufacturers' production of injectable drug delivery systems to meet global medical needs. The market in the post-pandemic period will grow significantly due to increased hospital visits and the launch of advanced drug delivery systems, among others.

The Implantable Drug Delivery segment is expected to be the largest during the forecast period

The Implantable Drug Delivery segment is estimated to hold the largest share. Implantable drug delivery is a specialised segment of the drug delivery market that involves the use of medical devices designed to deliver pharmaceutical agents directly into the body for controlled and sustained release. These devices, often implanted under the skin or within specific bodily tissues, can administer drugs over extended periods, reducing the need for frequent dosing. Implantable drug delivery systems are used in various medical applications, including the treatment of chronic conditions such as diabetes and pain management, offering patients convenience and improved therapeutic outcomes while minimising potential side effects. This segment represents an innovative approach to enhancing drug efficacy and patient compliance.

The Cardiovascular Diseases segment is expected to have the highest CAGR during the forecast period

The Cardiovascular Diseases segment is anticipated to have lucrative growth during the forecast period. Cardiovascular diseases (CVD) represent a significant and multifaceted segment within the drug delivery market. This sector is dedicated to developing innovative drug delivery systems and therapies aimed at preventing, managing, and treating conditions such as hypertension, coronary artery disease, heart failure, and stroke. Drug delivery technologies for CVD encompass a wide range of solutions, including controlled-release formulations, stents coated with medications to prevent artery blockage, and novel delivery methods for anticoagulants and antiplatelet agents. These advancements improve the efficacy of medications, enhance patient compliance, and reduce the risk of adverse cardiovascular events. Moreover, with CVD being a leading cause of mortality worldwide, the cardiovascular drug delivery market plays a pivotal role in mitigating this public health crisis by providing solutions that contribute to better outcomes and overall cardiovascular health.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The rising incidence of cancer and growing public knowledge of cancer treatments are the main causes of this region's market expansion. With a vast population, the Asia-Pacific region has experienced an increase in cancer prevalence in recent years as a result of changing lifestyles, environmental factors, and ageing populations. As a result, there are an increasing number of patients receiving treatment, which raises the need for the distribution of pharmaceutical drugs. Moreover, due to the increase in disposable income as well as the lucrative potential for major participants in the market, Asia-Pacific is expected to develop at the highest rate during the forecast period. Furthermore, manufacturers in India are increasing their production capacities to meet the rising demand for syringes, thereby fostering overall market growth across the region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. This is attributed to several factors, including the increased occurrence of chronic illnesses including diabetes, cancer, and respiratory allergies; increased patient adherence to novel drug delivery technology; and the concentration of notable individuals in this area. The market is expanding due to the presence of many significant players, including Novartis AG, Pfizer Inc., F. Hoffmann La-Roche Ltd., and Merck and Co., Inc., in the area. Moreover, the need for pharmaceutical drug delivery solutions in North America is growing rapidly due to the biopharmaceutical industry's development of numerous novel medications that can cure a range of non-communicable disorders.

Key players in the market

Some of the key players in the Drug Delivery Market include: Abbott, Bayer, AstraZeneca, Sanofi, GlaxoSmithKline, La Roche, Johnson & Johnson, Novartis AG, Merck, Pfizer, Antares Pharma, GSK, Accord Healthcare, Becton Dickinson and Co, Boston Scientific Corp, Baxter International Inc, Kindeva Drug Delivery LP, Gerresheimer AG, Sever Pharma Solutions and Boehringer Ingelheim International.

Key Developments:

In December 2022, Johnson & Johnson announced the launch of its ACUITY™ MRI SureScan™ pacemaker. This pacemaker is the first and only MRI-conditional pacemaker that is also compatible with Johnson & Johnson's ACUITY™ MRI SureScan™ defibrillator.

In November 2022, Sorin Group announced the launch of its Evia™ leadless pacemaker. This pacemaker is a small, wireless device that is implanted directly into the heart without the need for leads.

In October 2022, Arena Pharmaceuticals announced the approval of its drug, ravulizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ravulizumab is a long-acting, subcutaneously administered C5 complement inhibitor that provides sustained protection from hemolysis in patients with PNH.

In September 2022, Alnylam Pharmaceuticals announced the approval of its drug, vutrisiran, for the treatment of hereditary transthyretin amyloidosis (ATTR amyloidosis). Vutrisiran is a subcutaneously administered RNA interference (RNAi) therapy that targets the production of TTR protein.

In August 2022, Sanofi announced the approval of its drug, Dupixent, for the treatment of atopic dermatitis in adults and children aged 6 years and older. Dupixent is a human monoclonal antibody that targets the IL-4 and IL-13 cytokines.

Types Covered:

  • Injectable Drug Delivery
  • Transdermal Drug Delivery
  • Oral Drug Delivery
  • Topical Drug Delivery
  • Transmucosal Drug Delivery
  • Implantable Drug Delivery
  • Ocular Drug Delivery
  • Other Types

Device Types Covered:

  • Advanced
  • Conventional

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Distribution Channels

Applications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Central Nervous System Disorders
  • Respiratory Diseases
  • Other Applications

End Users Covered:

  • Home Care Settings
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Delivery Market, By Type

  • 5.1 Introduction
  • 5.3 Injectable Drug Delivery
  • 5.4 Transdermal Drug Delivery
  • 5.5 Oral Drug Delivery
  • 5.6 Topical Drug Delivery
  • 5.7 Transmucosal Drug Delivery
  • 5.8 Implantable Drug Delivery
  • 5.9 Ocular Drug Delivery
  • 5.1 Other Types

6 Global Drug Delivery Market, By Device Type

  • 6.1 Introduction
  • 6.2 Advanced
  • 6.3 Conventional

7 Global Drug Delivery Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Other Distribution Channels

8 Global Drug Delivery Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Cardiovascular Diseases
  • 8.4 Diabetes
  • 8.5 Central Nervous System Disorders
  • 8.6 Respiratory Diseases
  • 8.7 Other Applications

9 Global Drug Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Home Care Settings
  • 9.3 Hospitals and Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Other End Users

10 Global Drug Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott
  • 12.2 Bayer
  • 12.3 AstraZeneca
  • 12.4 Sanofi
  • 12.5 GlaxoSmithKline
  • 12.6 La Roche
  • 12.7 Johnson & Johnson
  • 12.8 Novartis AG
  • 12.9 Merck
  • 12.10 Pfizer
  • 12.11 Antares Pharma
  • 12.12 GSK
  • 12.13 Accord Healthcare
  • 12.14 Becton Dickinson and Co
  • 12.15 Boston Scientific Corp
  • 12.16 Baxter International Inc
  • 12.17 Kindeva Drug Delivery LP
  • 12.18 Gerresheimer AG
  • 12.19 Sever Pharma Solutions
  • 12.20 Boehringer Ingelheim International

List of Tables

  • Table 1 Global Drug Delivery Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Delivery Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Drug Delivery Market Outlook, By Injectable Drug Delivery (2021-2030) ($MN)
  • Table 4 Global Drug Delivery Market Outlook, By Transdermal Drug Delivery (2021-2030) ($MN)
  • Table 5 Global Drug Delivery Market Outlook, By Oral Drug Delivery (2021-2030) ($MN)
  • Table 6 Global Drug Delivery Market Outlook, By Topical Drug Delivery (2021-2030) ($MN)
  • Table 7 Global Drug Delivery Market Outlook, By Transmucosal Drug Delivery (2021-2030) ($MN)
  • Table 8 Global Drug Delivery Market Outlook, By Implantable Drug Delivery (2021-2030) ($MN)
  • Table 9 Global Drug Delivery Market Outlook, By Ocular Drug Delivery (2021-2030) ($MN)
  • Table 10 Global Drug Delivery Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Drug Delivery Market Outlook, By Device Type (2021-2030) ($MN)
  • Table 12 Global Drug Delivery Market Outlook, By Advanced (2021-2030) ($MN)
  • Table 13 Global Drug Delivery Market Outlook, By Conventional (2021-2030) ($MN)
  • Table 14 Global Drug Delivery Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 15 Global Drug Delivery Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 16 Global Drug Delivery Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 17 Global Drug Delivery Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 18 Global Drug Delivery Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 19 Global Drug Delivery Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Drug Delivery Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 21 Global Drug Delivery Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 22 Global Drug Delivery Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 23 Global Drug Delivery Market Outlook, By Central Nervous System Disorders (2021-2030) ($MN)
  • Table 24 Global Drug Delivery Market Outlook, By Respiratory Diseases (2021-2030) ($MN)
  • Table 25 Global Drug Delivery Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 Global Drug Delivery Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Drug Delivery Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 28 Global Drug Delivery Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 29 Global Drug Delivery Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 30 Global Drug Delivery Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.